prodchem
Aug 28, 2026
Eli Lilly’s acquisition of Orna Therapeutics in February 2026 marked an early and strategically important move into in-vivo cell engineering, giving the pharmaceutical giant access to a technology platform designed to generate therapeutic cells directly inside the patient.
The transaction, worth up to $2.4 billion in cash, including an upfront payment and development milestones, expanded Lilly’s ambitions in genetic medicine and cell therapy. At the center of the deal was Orna’s combination of engineered circular RNA (circRNA) and lipid nanoparticle (LNP) delivery technology.
Although the strategy is sometimes characterized broadly as an entry into in-vivo gene editing, Orna’s initial platform is more specifically focused on in-vivo cell engineering. Rather than editing a patient's genome directly, the technology is intended to deliver RNA instructions that enable the body to produce therapeutic proteins or engineer immune cells.
Orna Therapeutics was founded around a fundamentally different approach to cell therapy.
Conventional CAR-T treatment generally involves removing a patient's T cells, genetically modifying them outside the body, expanding the cells and then infusing them back into the patient.
That process can be expensive, time-consuming and operationally complex.
Orna's approach attempts to move much of that process inside the patient's body.
Its technology combines circular RNA with lipid nanoparticles to deliver genetic instructions directly to cells. The goal is for the patient's own cells to temporarily produce the therapeutic proteins or cellular machinery required to treat disease.
For Lilly, this offered the possibility of developing a new generation of cell therapies without relying entirely on conventional ex-vivo manufacturing.
The scientific foundation of the Orna deal is its circular RNA platform.
Unlike conventional linear messenger RNA, circular RNA is engineered into a closed-loop structure. Orna believes this configuration can potentially provide more durable protein expression than some existing RNA approaches.
The company combines its circular RNA technology with lipid nanoparticles designed to deliver the RNA into target cells.
The basic concept can be represented as:
Circular RNA → LNP delivery → Target cells → Therapeutic protein expression → Disease treatment
The platform could potentially be adapted to produce different therapeutic proteins or engineer immune cells for different diseases.
That makes the technology more interesting to a large pharmaceutical company than a single-product acquisition.
The principal asset Lilly obtained was ORN-252, a clinical-trial-ready CD19-targeted in-vivo CAR-T therapy designed for B-cell-driven autoimmune diseases.
CD19 is a target expressed on B cells, making it relevant to diseases in which abnormal or pathogenic B cells contribute to disease.
The concept is particularly interesting because CAR-T therapies have increasingly moved beyond oncology into autoimmune diseases.
Early clinical research with conventional CAR-T approaches has suggested that eliminating disease-driving B cells and allowing the immune system to rebuild could potentially produce deep and durable responses in some autoimmune conditions.
Orna's objective is to achieve a similar therapeutic concept while avoiding much of the complexity associated with conventional autologous CAR-T manufacturing.
This is where the Orna acquisition becomes strategically important.
Traditional CAR-T can be viewed as a manufacturing process followed by treatment.
The patient's cells are:
Collected.
Genetically engineered.
Expanded.
Quality tested.
Returned to the patient.
Orna is attempting to redesign this model so that the patient's body performs much of the engineering process itself.
Its circular RNA and LNP platform is intended to provide the instructions required for T cells to become CAR-T cells directly in the body.
If successful, such an approach could potentially simplify treatment logistics and reduce some of the manufacturing barriers associated with conventional cell therapy.
The biggest strategic attraction may be scalability.
Ex-vivo CAR-T therapies require specialized manufacturing infrastructure, individualized production and complex logistics. These requirements can make treatment difficult to deliver at large scale.
An effective in-vivo CAR-T therapy could potentially shift the manufacturing burden away from individualized cell production.
Instead of manufacturing a separate CAR-T product for every patient, a standardized drug-like formulation could theoretically be administered to patients, with the therapy generated inside their bodies.
That does not mean Orna's approach has already solved these challenges. Safety, targeting, durability and control of cellular engineering remain critical development questions.
But the potential economic and logistical advantages help explain why Lilly viewed the technology as strategically important.
The Orna transaction was explicitly described by Lilly as providing a broad platform for long-term innovation in genetic medicine and in-vivo cell engineering.
That wording is significant.
Lilly was not simply acquiring ORN-252.
The company was acquiring access to a technology platform that could potentially be used to develop multiple types of genetic medicines.
The same basic architecture—RNA engineering combined with targeted delivery—could potentially be adapted for different therapeutic applications.
This platform-oriented approach is increasingly important in pharmaceutical M&A because a successful underlying technology can generate multiple future products.
The acquisition also needs to be viewed alongside Lilly's other 2026 transactions.
In April, Lilly agreed to acquire Kelonia Therapeutics for its in-vivo CAR-T technology based on engineered lentiviral particles. Kelonia's platform is designed to selectively enter T cells inside the body and genetically program them to become CAR-T cells.
The two transactions therefore give Lilly exposure to different approaches to in-vivo CAR-T engineering.
Orna uses circular RNA and LNP technology, while Kelonia uses an in-vivo gene-delivery and integration system based on engineered lentiviral particles.
That distinction is strategically valuable.
Rather than committing to one technological route, Lilly is building capabilities across multiple approaches to bringing cell therapy inside the body.
The two acquisitions also demonstrate how Lilly's 2026 business-development strategy evolved.
Lilly announced acquisitions of Orna, Centessa, Kelonia and Ajax during the first quarter. The company subsequently completed those transactions and added further deals later in the year.
The strategy spans several areas:
Orna: circular RNA and in-vivo cell engineering
Kelonia: in-vivo CAR-T and gene delivery
Ajax: Type II JAK2 inhibition
Centessa: sleep-wake disorders
Ventyx: inflammation and NLRP3 biology
This indicates that Lilly is using acquisitions to build a diversified pipeline rather than concentrating all of its capital on a single therapeutic technology.
Orna's lead program also reflects a major shift in the CAR-T market.
CAR-T therapy was originally developed primarily for blood cancers. Increasingly, researchers are exploring whether the same ability to eliminate specific immune-cell populations can be used to treat autoimmune disease.
B-cell-driven autoimmune disorders are particularly attractive because CD19 provides a well-established target for B-cell depletion.
The potential goal is not simply short-term symptom control but a reset of the immune system.
Lilly specifically highlighted Orna's potential to develop in-vivo CAR-T therapies capable of resetting the immune system in B-cell-driven autoimmune diseases.
If successful, this could position Orna's platform at the intersection of cell therapy, immunology and genetic medicine.
The transaction value reflects the potential Lilly sees in the technology.
Under the agreement, Orna shareholders could receive up to $2.4 billion, including an upfront payment and additional payments linked to clinical-development milestones.
The milestone structure is important because it allows Lilly to link part of the acquisition cost to future development progress.
That reduces some of the risk associated with buying an early-stage biotechnology company while preserving significant potential value for Orna shareholders if the programs succeed.
For Lilly, however, the financial commitment still represents a substantial bet on a technology whose ultimate clinical value has yet to be established.
The broader significance of the Orna deal lies in the potential evolution of cell therapy.
The first generation of CAR-T therapies demonstrated that a patient's own immune cells could be engineered into powerful therapeutic agents.
The next question is whether those cells can be engineered inside the body.
If that transition succeeds, cell therapy could begin to resemble conventional pharmaceutical treatment in terms of administration and scalability.
Patients could potentially receive a standardized therapy rather than undergo a lengthy individualized manufacturing process.
That could dramatically expand the number of patients who can realistically access advanced cell therapies.
The promise of in-vivo cell engineering comes with substantial challenges.
The delivery system must reach the correct cells.
The therapeutic RNA must produce sufficient protein expression.
The immune system must tolerate the delivery technology.
Researchers must also ensure that unwanted cells are not engineered and that the resulting therapeutic cells behave predictably.
For CAR-T applications, durability is another major question. A treatment must generate enough functional CAR-T cells to produce the desired therapeutic effect without creating unacceptable immune-related toxicity.
These challenges mean that the Orna platform remains an experimental technology rather than an established replacement for conventional CAR-T.
The Orna acquisition becomes even more significant when viewed alongside Lilly's later Kelonia transaction.
By acquiring Orna and then Kelonia, Lilly gained access to two distinct approaches for generating CAR-T cells inside patients.
This creates an unusual strategic position.
Rather than waiting for one in-vivo technology to emerge as the clear winner, Lilly is effectively building a portfolio around the broader concept of in-vivo cell engineering.
The company can now evaluate different delivery mechanisms, genetic payloads and therapeutic applications.
That could become valuable if the field expands rapidly over the next several years.
The simplest way to understand the Orna transaction is that Lilly bought three interconnected assets:
1. A circular RNA platform
A technology designed to produce potentially durable expression of therapeutic proteins.
2. An LNP delivery platform
A delivery system intended to transport genetic instructions into target cells.
3. An in-vivo CAR-T strategy
A clinical development program aimed at engineering a patient's T cells directly inside the body.
Together, these capabilities provide Lilly with a potential foundation for developing therapies that blur the traditional boundaries between RNA medicines, gene therapy and cell therapy.
Lilly's acquisition of Orna Therapeutics was an early signal that the company intended to establish a meaningful position in in-vivo genetic medicine and cell engineering.
The approximately $2.4 billion transaction gave Lilly access to Orna's circular RNA and LNP technology and its lead ORN-252 program, an in-vivo CD19 CAR-T therapy being developed for B-cell-driven autoimmune diseases.
The deal is particularly notable because it points toward a possible transition in cell therapy—from manufacturing engineered cells outside the body to creating therapeutic cells directly inside patients.
Lilly's subsequent acquisition of Kelonia strengthened that direction by adding another in-vivo CAR-T delivery technology.
For now, the science remains experimental, and the clinical development path will determine whether these technologies can deliver on their promise. But strategically, Orna gave Lilly an early foothold in a field that could eventually reshape how gene medicines and cell therapies are manufactured, delivered and commercialized.
Featured Product
Found this useful?
Continue Reading
Ajax's AJ1-11095 candidate still faces standard FDA clinical trial review requirements following Lilly's acquisition. The development path could influence future demand for pharmaceutical chemicals and manufacturing inputs.
Clariant's incoming CFO takes office as European ESG disclosure requirements continue to influence financial reporting. Chemical buyers should watch how stronger sustainability reporting affects supplier data, costs and procurement decisions.
IG4 Capital's pending controlling stake in Braskem includes exposure to the company's sugarcane-derived biobased ethylene business
